Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Individualized Bosutinib Dose Adjustments Lend a Manageable AE Profile in Pretreated CML

October 22nd 2024

Jorge Cortes, MD, discusses findings with bosutinib in CML and the importance of dose adjustment as a strategy for managing bosutinib-related AEs.

Acalabrutinib Plus Venetoclax/Rituximab Yields 100% ORR in Treatment-Naive Mantle Cell Lymphoma

October 22nd 2024

Acalabrutinib plus venetoclax and rituximab generated a 100% response rate in treatment-naive mantle cell lymphoma.

ONCT-534 Reduces PSA Levels, Is Tolerable in Relapsed/Refractory mCRPC

October 22nd 2024

ONCT-534 reduced prostate-specific antigen levels in patients with relapsed/refractory metastatic castration-resistant prostate cancer.

TG4001 Plus Avelumab Fails to Boost PFS in Recurrent/Metastatic, HPV16+ Cervical, Anogenital Tumors

October 22nd 2024

The addition of TG4001 to avelumab failed to improve progression-free survival in HPV16-positive cervical and anogenital tumors.

The OncFive: Top Oncology News and Trends for the Week of 10/13

October 19th 2024

Zolbetuximab wins approval for CLDN18.2-positive gastric/GEJ cancer, TTFields joins the NSCLC armamentarium, and more of this week's top news in oncology.

FDA Approves Zolbetuximab Plus Chemo for CLDN18.2+ Gastric or GEJ Adenocarcinoma

October 18th 2024

The FDA approved zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.

Botensilimab Plus Balstilimab Elicits Durable Responses in Refractory Metastatic Sarcoma

October 18th 2024

Breelyn Wilky, MD, discusses updated efficacy and safety findings following treatment of botensilimab and balstilimab in refractory metastatic sarcoma.

Gilead to Withdraw US Indication for Sacituzumab Govitecan in Metastatic Urothelial Cancer

October 18th 2024

Gilead will voluntarily withdraw the United States indication for sacituzumab govitecan in metastatic urothelial cancer.

Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC

October 18th 2024

Hidehito Horinouchi, MD, PhD, discusses safety data from the ALINA trial of adjuvant alectinib in ALK-positive non–small cell lung cancer.

Bel-Sar Elicits Complete Responses in NMIBC

October 17th 2024

Belzupacap sarotalocan produced complete responses in patients with low-grade non–muscle-invasive bladder cancer.

ARANOTE Data Highlight Darolutamide Plus ADT as a Potential Chemo-Free Option in mHSPC

October 17th 2024

Fred Saad, MD, FRCS, discusses efficacy and safety data for darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

October 17th 2024

Dr Foss discusses the significance of the FDA approval of denileukin diftitox for patients with relapsed/refractory CTCL.

Daratumumab/Lenalidomide Maintenance Deepens Responses, Boosts MRD-Negativity Rates in Myeloma After ASCT

October 17th 2024

Ashraf Z. Badros, MBCHB, discusses the use of daratumumab plus lenalidomide as maintenance therapy after transplant in newly diagnosed multiple myeloma.

Updated RAMP 201 Data to Support NDA Submission for Avutometinib/Defactinib Combo in Recurrent KRAS+ Ovarian Cancer

October 17th 2024

Updated RAMP 201 data will support an NDA submission to the FDA for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.

Tafasitamab Plus Lenalidomide Wins Approval in Mexico for ASCT-Ineligible, R/R DLBCL

October 17th 2024

Tafasitamab plus lenalidomide followed by tafasitamab monotherapy has been approved in Mexico for ASCT-ineligible, relapsed/refractory DLBCL.

T-DXd Demonstrates Efficacy in HER2+ Metastatic Breast Cancer With Stable or Active Brain Metastases

October 16th 2024

Nancy U. Lin, MD, discusses findings from the DESTINY-Breast12 trial of trastuzumab deruxtecan in advanced HER2-positive breast cancer with brain metastases.

Venetoclax/Rituximab Retreatment Produces Durable Responses in CLL

October 16th 2024

Retreatment with venetoclax plus rituximab generated responses in patients with CLL who had responded to and progressed after initial venetoclax treatment.

Osimertinib Plus Savolitinib Generates Durable Responses in EGFR-Mutant, MET-Amplified NSCLC

October 16th 2024

Adding savolitinib to osimertinib produced clinically meaningful responses in EGFR-mutant, MET-overexpressed NSCLC following progression on osimertinib.

VCN-01 Earns Orphan Medicinal Product Designation in Europe for Retinoblastoma

October 16th 2024

The European Commission has granted orphan medicinal product designation to VCN-01 for the treatment of patients with retinoblastoma.

Galinpepimut-S Earns FDA Rare Pediatric Disease Designation for AML

October 16th 2024

The FDA has granted rare pediatric disease designation to galinpepimut-S for acute myeloid leukemia.